On September 9, 2025 Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, reported an agreement with Eli Lilly and Company (Lilly) that enables the company to use Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug discovery models that have been trained on Lilly’s proprietary research data (Press release, Circle Pharma, SEP 9, 2025, View Source [SID1234655875]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Circle Pharma will leverage Lilly TuneLab to further strengthen its AI/ML capabilities and proprietary MXMO platform, which is designed to overcome key challenges in macrocycle drug development to enable the creation of intrinsically cell-permeable and orally bioavailable macrocycle therapies, including for historically undruggable targets. Circle Pharma’s lead program, CID-078, is a first-in-class, orally bioavailable cyclin A/B RxL inhibitor that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
"We are thrilled to partner with Lilly and gain access to TuneLab," said Constantine Kreatsoulas, Ph.D., senior vice president, head of discovery technology sciences at Circle Pharma. "This collaboration will further enhance our MXMO platform, which enables us to better predict how various types of macrocycles may be able to penetrate cells, show oral bioavailability, exhibit desirable drug-like properties, and be manufactured at scale. This collaboration comes at an important time of growth at Circle Pharma with our lead program, CID-078, now in clinical development and our preclinical pipeline advancing rapidly to address cyclins and other historically undruggable targets in oncology."
This agreement is part of the Lilly Catalyze360 model, a comprehensive approach to empower early-stage biotechs to advance groundbreaking science by providing access to capital, cutting-edge lab space and technology, and drug development talent and resources.
About Circle Pharma’s MXMO platform
Circle Pharma’s proprietary MXMO platform combines computationally driven drug design along with advanced, fully synthetic macrocycle chemistry. Through this platform, Circle Pharma’s scientists screen vast permeability-biased physical and virtual macrocycle libraries to identify early hit compounds. Artificial Intelligence (AI), Machine Learning (ML), and rigorous physics-based simulations are used to assess many designs simultaneously and to rapidly explore structure-activity relationships for hit-to-lead progression. These diverse compounds are then synthesized in the lab, utilizing both natural and unnatural chemical building blocks, many of which are custom and proprietary to Circle Pharma, to evaluate them as lead investigational macrocycles.